

RealRate

PHARMACEUTICAL 2017



ENANTA PHARMACEUTICALS INC Rank 3 of 292







PHARMACEUTICAL 2017



ENANTA PHARMACEUTICALS INC Rank 3 of 292



The relative strengths and weaknesses of ENANTA PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENANTA PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 89% points. The greatest weakness of ENANTA PHARMACEUTICALS INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 0.74% points.

The company's Economic Capital Ratio, given in the ranking table, is 332%, being 329% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	232,156
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,889
Liabilities, Non-Current	2,042
Other Assets	41,117
Other Compr. Net Income	-14
Other Expenses	10,894
Other Liabilities	1,410
Other Net Income	1,719
Other Revenues	88,268
Property and Equipment	8,004
Research and Development	40,461
Selling, General and Administrative Expense	16,966

Output Variable	Value in 1000 USD
Assets	281,277
Liabilities	11,341
Expenses	68,321
Revenues	88,268
Stockholders Equity	269,936
Net Income	21,666
Comprehensive Net Income	21,659
Economic Capital Ratio	332%

